Phenotype-Driven Identification of Drug Targets For Post-COVID-19 Anosmia

Anosmia (loss of sense of smell) is one symptom of COVID-19 which can linger long after acute infection has passed, with major impact on quality of life. Given the number of people impacted by COVID-19-related anosmia, there is an urgent need to identify effective therapeutics in a faster fashion than using traditional drug discovery and development methods. We used our knowledge graph, the Phenograph, to navigate from phenotypes to genes to drug targets, to rapidly find druggable targets associated with anosmia.


View the full study here.

Previous
Previous

Drivers of Mortality in COVID ARDS Depend on Patient Sub-Type

Next
Next

Poster Presentation – American Epilepsy Society (AES) 2022